Zealand Pharma shares drop 20% as obesity drug side effects raise concerns

Zealand Pharma shares fell more than 20% in early trading after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments. The results weaken the drug's competitive profile and raise questions about its commercial prospects. The move is likely to pressure the stock materially, though the news is company-specific rather than sector-wide.

Analysis

Zealand Pharma shares fell more than 20% in early trading after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments. The results weaken the drug's competitive profile and raise questions about its commercial prospects. The move is likely to pressure the stock materially, though the news is company-specific rather than sector-wide.